Clinical Trial Update: Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

Phase 2 trial of azacitidine, darbepoetin alfa, erythropoietin, and G-CSF in myelodysplastic syndromes; study terminated with posted results in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Erythropoietin (erythropoietin)
• Filgrastim (G-CSF) (filgrastim)
• darbepoetin alfa (darbepoetin alfa)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Leukemia, Myelodysplastic Syndromes | Phase 2 | Status: TERMINATED | Results posted: 2012-04-17